CG
TCRT icon

Cutler Group’s Alaunos Therapeutics TCRT Stock Holding History

Cutler Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-59
Closed -$7K – 5199
2022
Q3 		$7K Buy
+59
New +$17.1K ﹤0.01% 3416
2022
Q1 		– Sell
-17
Closed -$4K – 6024
2021
Q4 		$4K Hold
17
– – ﹤0.01% 4392
2021
Q3 		$3K Hold
17
– – ﹤0.01% 4864
2021
Q2 		$2K Buy
+17
New +$7.93K ﹤0.01% 5083
2017
Q4 		– Sell
-46
Closed -$41K – 5896
2017
Q3 		$41K Buy
+46
New +$40.9K ﹤0.01% 2428
2017
Q2 		– Sell
-337
Closed -$15K – 7056
2017
Q1 		$15K Sell
337
-678
-67% -$631K ﹤0.01% 3645
2016
Q4 		$118K Buy
1,015
+422
+71% +$380K ﹤0.01% 1763
2016
Q3 		$59K Buy
593
+552
+1,346% +$444K ﹤0.01% 2301
2016
Q2 		$41K Buy
41
+2
+5% +$2.18K ﹤0.01% 2568
2016
Q1 		$41K Sell
39
-502
-93% -$514K ﹤0.01% 2537
2015
Q4 		$294K Buy
+541
New +$895K 0.02% 902

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cutler Group's TCRT Position: Q4 2022 in Review

Cutler Group sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 27 shares — an estimated $7K sold.

Cutler Group first reported a position in TCRT in Q4 2015 and held it in 16 quarters. The position peaked at $579K in Q4 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Cutler Group reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 27 Alaunos Therapeutics shares in Q4 2022, an estimated $7K.
  • Cutler Group first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 16 quarters.
  • Cutler Group's Alaunos Therapeutics position peaked at $579K in Q4 2015.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.